Abstract Library

#4453 Multiple sporadic neuroendocrine tumours: A diagnostic challenge

Introduction: Neuroendocrine tumours (NETs) show substantial clinical and histological heterogeneity. The presence of multiple primary NETs represents a diagnostic and therapeutic challenge as clinicians have to differentiate between primary and metastatic NETs.

Conference:

Presenting Author: Tsoli M

Authors: Tsoli M, Koumarianou A, Panagaki M, Ioannidou K, Kyriakopoulos G,

Keywords: neuroendocrine tumour, double primary, immunohistochemistry,

#4258 Unanticipated heterogeneity in high-grade large-cell neuroendocrine carcinoma pinpoints cell sub-state specific therapeutic targets

Introduction: High-grade pancreatic neuroendocrine carcinoma (panNEC) pose challenges in terms of classification and treatment. While molecular genetics have made strides in deciphering significant inter-tumor heterogeneity, the extent of intra-tumoral heterogeneity and lineage plasticity remains unexplored.

Conference:

Presenting Author:

Authors: Debnath O, Detjen K, Berger H, Kirchner P, Marinoni I,

Keywords: PanNEC, Single cell RNAseq,

#4196 Metastatic potential and associated mortality in a Greek cοhort of 123 MEN1 patients

Introduction: Prevalence of distant stage disease and overall mortality rates vary considerably among patients with multiple endocrine neoplasia type 1 (MEN1).

Conference:

Presenting Author: Papadopoulou-Marketou N

Authors: Papadopoulou-Marketou N, Daskalakis K, Chondrogianni M, Tsoli M, Kaltsas G,

Keywords: MEN1, pancreatic neuroendocrine tumor, thymus cancer,

#4114 Delays in the dosing administration of PRRT in advanced neuroendocrine tumors – Is there an adverse impact?

Introduction: Peptide receptor radionuclide therapy (PRRT) has emerged as a major therapeutic component in the overall management of advanced neuroendocrine tumors (NETs). In Greece, the treatment has been performed for several years, however because of reimbursement issues, especially during the financial crisis in Greece, there is usually a delay between the administered doses beyond the recommended 6-8 weeks interval.

Conference:

Presenting Author:

Authors: Georgakopoulos A, Tsoli M, Koumarianou A, Papadopoulou N, Panagaki M,

Keywords: PRRT, Progression-free survival, overall survival,

#3995 Pelvic metastases in patients with neuroendocrine tumors: A rare site of metastases

Introduction: Pelvic metastases (PMs) in patients with neuroendocrine tumors (NETs) are rare and develop predominately in women with small intestinal NETs (Si-NETs). The characteristics of NET related PMs and the efficacy of different management options have been poorly investigated.

Conference:

Presenting Author:

Authors: Thuringer J, Tsoli M, Parker G, Sarma A, Panagaki M,

Keywords: pelvic metastases, prognosis, oophorectomy, PRRT,